Pear Therapeutics, Inc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD from Q4 2020 to Q4 2022

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Pear Therapeutics, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and growth rate from Q4 2020 to Q4 2022.
  • Pear Therapeutics, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending December 31, 2022 was $6.94M, a 287% increase year-over-year.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2022 $6.94M +$5.15M +287% Dec 31, 2022 10-K 2023-03-31
Q3 2022 $7.18M Sep 30, 2022 10-Q 2022-11-14
Q2 2022 $5.38M Jun 30, 2022 10-Q 2022-08-11
Q1 2022 $4.13M Mar 31, 2022 10-Q 2022-05-16
Q4 2021 $1.79M +$1.54M +598% Dec 31, 2021 10-K 2023-03-31
Q4 2020 $257K Dec 31, 2020 10-K 2022-03-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.